FLT3,   General AML

ASCO 2018 | New agents in AML

Cynthia Umukoro , Jun 14, 2018

General AML

ASCO 2018 | Immune checkpoints in AML

Cynthia Umukoro , Jun 13, 2018

FLT3

Mark Levis | ASCO 2018 | Maintenance therapy with gilteritinib in FLT3-ITD+ AML

Cynthia Umukoro , Jun 12, 2018

IDH1/2

ASCO 2018 | A phase I dose escalation study of FT-2102 in IDH1 mutated AML patients

Anna Bartus , Jun 11, 2018

General AML

ASCO 2018 | Early results from parallel phase I studies of haploidentical expanded NK cells after fludarabine/cytarabine in R/R…

Cynthia Umukoro , Jun 8, 2018

General AML

Alice Mims | ASCO 2018 | What are the current challenges facing AML treatment?

Cynthia Umukoro , Jun 8, 2018

General AML

ASCO 2018 | Venetoclax in combination with decitabine or azacitidine in elderly patients with AML induces durable response

Cynthia Umukoro , Jun 7, 2018

General AML

Courtney DiNardo | ASCO 2018 | Venetoclax plus HMAs in elderly AML patients

Cynthia Umukoro , Jun 7, 2018

IDH1/2

Uma Borate | ASCO 2018 | Impact of targeted therapy on treatment of AML

Cynthia Umukoro , Jun 4, 2018

IDH1/2,   General AML

Eunice Wang | ASCO 2018 | What are the new advances in AML treatment?

Cynthia Umukoro , Jun 4, 2018